Functional expression of sodium-glucose transporters in cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 30, 2015, Pages E4111-E4119

  Scafoglio, Claudio ^a   Hirayama, Bruce A ^a   Kepe, Vladimir ^a   Liu, Jie ^a   Ghezzi, Chiara ^a   Satyamurthy, Nagichettiar ^a   Moatamed, Neda A ^a   Huang, Jiaoti ^a   Koepsell, Hermann ^b   Barrio, Jorge R ^a   Wright, Ernest M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Pancreatic cancer; Prostate cancer; SGLT2; SGLT2 inhibitors

Indexed keywords

DEOXYRIBONUCLEOTIDE; GLUCOSE; RIBONUCLEOTIDE REDUCTASE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ALPHA-METHYL-4-DEOXY-4-((18)F)FLUORO-D-GLUCOPYRANOSIDE; FLUORINE; GLUCOSE TRANSPORTER; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SLC5A2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CELL CYCLE ARREST; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KIDNEY CORTEX; KIDNEY PROXIMAL TUBULE; MOUSE; MYOFIBROBLAST; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; THERAPY; TUMOR GROWTH; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CHEMISTRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; KIDNEY; MALE; METABOLISM; NECROSIS; PANCREATIC NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TRANSPORT AT THE CELLULAR LEVEL;

ADENOCARCINOMA; ANIMALS; BIOLOGICAL TRANSPORT; FEMALE; FLUORINE RADIOISOTOPES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MICE; NECROSIS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84938152222     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1511698112     Document Type: Article

References (56)

1. Ganapathy-Kanniappan S, Geschwind JF (2013) Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer 12:152.
2. Teicher BA, Linehan WM, Helman LJ (2012) Targeting cancer metabolism. Clin Cancer Res 18(20):5537-5545.
3. Tennant DA, Durán RV, Gottlieb E (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10(4):267-277.
4. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309-314.
5. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11(2):85-95.
6. Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27:441-464.
7. Ganapathy V, Thangaraju M, Prasad PD (2009) Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol Ther 121(1):29-40.
8. Mueckler M, Thorens B (2013) The SLC2(GLUT) family of membrane transporters. Mol Aspects Med 34(2-3):121-138.
9. Czernin J, Benz MR, Allen-Auerbach MS (2010) PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol 73(3):470-480.
10. Czernin J, Phelps ME (2002) Positron emission tomography scanning: Current and future applications. Annu Rev Med 53:89-112.
11. Krause BJ, Schwarzenböck S, Souvatzoglou M (2013) FDG PET and PET/CT. Recent Results Cancer Res 187:351-369.
12. Gallamini A, Zwarthoed C, Borra A (2014) Positron emission tomography (PET) in oncology. Cancers (Basel) 6(4):1821-1889.
13. Matsumoto I, et al. (2013) 18-fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 11(6):712-718.
14. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y (2013) FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: A meta-analysis. World J Gastroenterol 19(29):4808-4817.
15. 18F-fluorodeoxyglucose PET/CT: Utility and limitations. Eur J Nucl Med Mol Imaging 40(Suppl 1):S5-S10.
16. Bouchelouche K, et al. (2011) PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med 41(1):29-44.
17. Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91(2):733-794.
18. Wright EM (2013) Glucose transport families SLC5 and SLC50. Mol Aspects Med 34(2-3):183-196.
19. Yu AS, et al. (2010) Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol 299(6):C1277-C1284.
20. Yu AS, et al. (2013) Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol 304(3):C240-C247.
21. Blessing A, et al. (2012) Sodium/glucose co-transporter 1 expression increases in human diseased prostate. J Cancer Sci Ther 40(9):306-312.
22. Vrhovac I, et al. (October 11, 2014) Localizations of Na (+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch, 10.1007/s00424-014-1619-7.
23. Hummel CS, et al. (2012) Structural selectivity of human SGLT inhibitors. Am J Physiol Cell Physiol 302(2):C373-C382.
24. Zhou Q, Facciponte J, Jin M, Shen Q, Lin Q (2014) Humanized NOD-SCID IL2rg-/-mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett 344(1):13-19.
25. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17(1):16-23.
26. Tan MH, Chu TM (1985) Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour Biol 6(1):89-98.
27. Terami N, et al. (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 9(6):e100777.
28. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 375(9733):2223-2233.
29. Liang Y, et al. (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7(2):e30555.
30. Devineni D, et al. (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53(6):601-610.
31. Pei J, et al. (2004) Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs 15(3):243-253.
32. Damaraju VL, et al. (2007) Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer 7:121.
33. Wang W, et al. (2012) Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression. J Cancer Res Clin Oncol 138(9):1597-1605.
34. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):v7-v12.
35. Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diab Vasc Dis Res 12(2):78-89.
36. +-dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol 303(3):C348-C354.
37. Szablewski L (2013) Expression of glucose transporters in cancers. Biochim Biophys Acta 1835(2):164-169.
38. Itkonen HM, et al. (2013) O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res 73(16):5277-5287.
39. Ying H, et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656-670.
40. Lloyd PG, Hardin CD (2001) Caveolae and the organization of carbohydrate metabolism in vascular smooth muscle. J Cell Biochem 82(3):399-408.
41. Seidler NW (2013) Compartmentation of GAPDH. Adv Exp Med Biol 985:61-101.
42. Vallejo J, Hardin CD (2005) Expression of caveolin-1 in lymphocytes induces caveolae formation and recruitment of phosphofructokinase to the plasma membrane. FASEB J 19(6):586-587.
43. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70.
44. Sonveaux P, et al. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118(12):3930-3942.
45. Semenza GL (2008) Tumor metabolism: Cancer cells give and take lactate. J Clin Invest 118(12):3835-3837.
46. Icard P, Lincet H (2012) A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim Biophys Acta 1826(2):423-433.
47. Mayer A, Vaupel P (2013) Hypoxia, lactate accumulation, and acidosis: Siblings or accomplices driving tumor progression and resistance to therapy? Adv ExpMed Biol 789:203-209.
48. Jain RK (2014) Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26(5):605-622.
49. Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371(11):1039-1049.
50. de la Santa LG, Retortillo JA, Miguel AC, Klein LM (2014) Radiology of pancreatic neoplasms: An update. World J Gastrointest Oncol 6(9):330-343.
51. Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CH (2014) Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: A meta-analysis. Eur J Surg Oncol 40(7):794-804.
52. Wright EM, Barrio JR, Hirayama BA, Kepe V (2014) Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease. US Patent 8, 845, 99 B2.
53. Kreissl MC, et al. (2011) Influence of dietary state and insulin on myocardial, skeletal muscle and brain [18F]-fluorodeoxyglucose kinetics in mice. EJNMMI Res 1:8.
54. Charon Y, Lanièce P, Tricoire H (1998) Radio-imaging for quantitative autoradiography in biology. Nucl Med Biol 25(8):699-704.
55. Loening AM, Gambhir SS (2003) AMIDE: A free software tool for multimodality medical image analysis. Mol Imaging 2(3):131-137.
56. Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50(Suppl 1):11S-20S.